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We have studied the activity of reporter plasmids, carrying the Epstein-Barr virus (EBV) nuclear antigen (EBNA) promoters Wp and Cp, in a group of somatic cell hybrids obtained by fusing EBV-positive lymphoblastoid cell lines or group II/III Burkitt's lymphoma cell lines with non-B cell lines. In B/non-B cell hybrids of this type, B cell markers are extinguished as a rule, in parallel with the inactivation of Cp or Wp and downregulation of EBNA-2-6 expression. A Wp-carrying reporter construct was active in non-B cell lines. Only cells with a B cell phenotype could support the activity of Cp-carrying plasmids. EBNA-2 transactivated Cp only in B cells. Our data suggest that while Wp can be used for EBNA transcription in B and non-B cells, Cp activity is restricted to B cells. The inability of EBNA-2 to transactivate Cp in non-B cells indicates that other factors present in B cells might be involved in Cp transactivation.
Six virus-encoded nuclear antigens, EBNA-1-6, are expressed in lymphoblastoid cell lines (LCLs) obtained by in vitro infection of normal B cells with Epstein-Barr virus (EBV) (for review see Kieff et al., 1991) . The primary transcript from which all the EBNA messages are spliced is initiated at one of two alternative viral promoters, Cp and Wp (Bodescot et al., 1987; Sample et al., 1986; Speck et al., 1986) . Clonal lines of EBVcarrying immunoblasts use Wp or Cp in a mutually exclusive way (Woisetschlaeger et al., 1989) .
Wp is active at the initial stage of viral infection. EBNA-2 and EBNA-5 are the first viral proteins expressed; the former is a prerequisite for a switch to Cp usage (Woisetschlaeger et aI., 1991 ; Sung et al., 1991 ; Jin & Speck, 1992; Rooney et al., 1992) . EBNA-2 transactivation of Cp is dependent on its interaction with a DNA-binding protein, CBF1 (Ling et al., 1993) , identified as the recombination binding protein Jtc (RBPJK) (Henkel et al., 1994) .
In Burkitt's lymphoma (BL) cells that phenotypically resemble germinal centre B cells (group I BLs) only EBNA-1 is expressed and the Cp and Wp promoters are inactive . The choice between exclusive EBNA-1 and full EBNA-1-6 expression depends on the host cell phenotype (Ernberg et al., 1989;  * Author for correspondence. Fax +46 8 33 04 98. Rowe et al., 1986) . Our previous studies with somatic cell hybrids derived from the fusion of EBV carrying immunoblastic lines that express EBNA-1-6 with non-B cell lines have shown that hybrids that express the phenotype of the non-B parent down-regulate EBNA-2-6 but not EBNA-1 (Contreras-Brodin et al., 1991) , in parallel with the inactivation of Cp and Wp (Altiok et al., 1992) .
We introduced reporter plasmids carrying Wp or Cp into B/non-B cell hybrids that express EBNA-1 only, in order to examine the activity of these promoters in comparison to their activity with the parental cell lines and a variety of other lines (B, T and epithelial phenotype). A map of the EBV DNA fragments contained in the Cp and Wp promoter constructs is shown in Fig. 1 . Plasmid DNA (10-15 pg) was electroporated into a panel of B/non-B cell lines and hybrids. The cells were harvested 40-48 h after transfection. Extracts were prepared and assayed for chloramphenicol acetyl transferase (CAT) activity as described previously (Ricksten et al., 1988) .
The phenotype and EBV antigen expression of the hybrids and parental lines has been described previously (Contreras-Brodin et al., 1991) and is summarized together with the results of the transient transfections in Table 1 .
Non * Determined by the expression of CD19, CD20, CD23, CD39, HLA class II antigens and sig expression (Contreras-Brodin et al., 1991) . t Determined by S1 nuclease assay (Altiok et al., 1991) . :~ Percentage chloramphenicol acetylation relative to the activity of pSVECAT (100 %). Means of at least two independent transfections. § P3HR-1, HP-1, PUTKO, Daudi and DUTKO carry EBNA-2 deleted viral strains.
in the epithelial cell lines Colo 205 and MCF-7; and in the mouse fibroblast line A9HT. The pAC3CAT construct, which contains all known upstream elements controlling Cp except OriP (-1024/+76), and the pAC4CAT plasmid, in which the OriP element has been added (-3889/+ 76) were virtually inactive in all human non-B cell lines tested. Low CAT activity was detected in cell line A9HT with pAC3CAT. B cells. The activity patterns of Cp and Wp reporter plasmids in LCLs and group II/III BLs were similar to those previously reported by Nilsson et al. (1993) . The OriP-containing construct pAC4CAT showed high activity in the lymphoblastoid cell line KR-4 whereas CAT activity obtained with pAC3CAT and pAW1CAT was close to background levels. All the constructs had significant activity in the group II/III BL lines P3HR1, Daudi and Raji, with the exception of pAC3CAT in Daudi.
Hybrids. The OriP-containing construct pAC4CAT and pAC3CAT were inactive in all hybrids with a non-B cell phenotype tested, pAC4CAT was active at a low level in DUTKO and pAC3CAT was active in the A9HT/Raji hybrid. On the other hand, pAC4CAT was highly active in the hybrid HP-1, which displays a B cell activated phenotype. The pAW1CAT plasrnid was active in all hybrid lines except KH-1, of which the HeLa line is a parent.
In DG75 and Ramos cells, EBNA-2 activated pAC3CAT which carries the proximal Cp enhancer elements including the EBNA-2 responsive element. Transactivation by EBNA-2 was lower when OriP was present in the reporter plasmid (pAC4CAT). In contrast, the pAC4CAT and pAC3CAT plasmids were not active in all non-B cell lines tested, either in the absence or in the presence of EBNA-2 (Table 2) . EBNA-2 was expressed in about 20% of the transfected cells as corroborated after every cotransfection by ACIF staining.
Our previous studies with somatic cell hybrids derived by the fusion of LCLs and BLs with non-B cell lines have shown that the expression of EBNA-2-6 and the activity of the Cp or Wp promoters is down-regulated in the hybrids in parallel with the loss of B cell markers (Contreras-Brodin et al., 1991; Altiok et al., 1992) , suggesting that the B cell phenotype is necessary for the transcriptional activation of these promoters. Our present findings with reporter constructs confirm this for Cp but not for Wp.
It has been reported that Wp-carrying reporter constructs are active in EBV negative B cell lines (Ricksten et al., 1988) , indicating that the activity of the Wp promoter does not require viral products, but is sustained by cellular factors only. This is consistent with the preferential use of the Wp promoter for the initial transcription of EBNA-1-6 message in freshly infected B cells. The unrestricted activity of Wp in cell lines of erythroid, myeloid, epithelial and T lymphoid origin indicates that Wp can become activated in EBV-infected cells of non-B origin.
The OriP/Cp construct (pAC4CAT) was active in cell lines KR-4 and Raji, and at lower levels in P3HR-1 and Daudi, confirming earlier findings (Nilsson et al., 1993) which show that an activated cellular phenotype is required to activate the Cp in OriP-containing plasmids. pAC4CAT was virtually inactive in the non-B cell lines tested and in hybrids that have lost the B cell phenotype.
Cp is transactivated by the binding of EBNA-1 to OriP (Sugden & Warren, 1989) by EBNA-2 (Woisetschlaeger et al., 1991; Sung et al., 1991) and by EBNA-6 (Robertson et al., 1995) . The regulatory effect of EBNA-2 and EBNA-6 is carried out by their interaction with the cellular factor CBF-1/RBPJ~c (Ling et al., 1993; Robertson et al., 1995) . The complexes bind to a cognate sequence upstream of Cp thereby modulating its activity. Three observations indicate that additional factors present in cells with an immunoblastic phenotype might interact upstream of the EBNA-2 responsive element to induce maximal Cp activity.
1. pAC3CAT is practically inactive in KR-4 and other previously studied (Nilsson et al., 1993) LCLs and group III BLs, while pAC4CAT is highly active in these cell types. This suggests that in these cell types the elements present in the -1024/+ 76 region (including the CBF-1/RBPJK binding site) are not active and that the region between -1024 to -3889 is indispensable for the activity of Cp.
2. The EBNA-2 negative lines P3HR-1, Daudi, and the B cell-like hybrid HP-1 can sustain the activity of pAC4CAT in the absence of EBNA-2, indicating that the promoter activity observed is contributed by the activated phenotype of these cells, and/or by viral factors other than EBNA-2.
3. The EBNA-2 induced transactivation of Cp, observed exclusively in B cells, never reaches the levels obtained when pAC4CAT is transfected into activated B cells (LCLs).
The results presented here show, that in contrast to Wp, which can be active in a wide number of cell phenotypes, Cp is a B cell-specific promoter that reaches maximal activity in EBV-carrying ceils of immunoblastic type.
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